C4 Therapeutics (CCCC) Other Gross PP&E Adjustments (2019 - 2026)
C4 Therapeutics' quarterly Other Gross PP&E Adjustments came in at -$23.5 million in Q1 2026, up 42.49% year-on-year from -$16.5 million in Q1 2025, and up 39.35% quarter-over-quarter from -$38.7 million in Q4 2025.
C4 Therapeutics has reported Other Gross PP&E Adjustments for 8 years, with the latest figure at -$23.5 million in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 42.49% year-over-year to -$23.5 million; the trailing twelve-month figure through Mar 2026 stood at -$23.5 million (up 42.49% YoY), and the FY2025 full-year result was -$38.7 million, up 27.62% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at -$23.5 million, up from -$38.7 million in the prior quarter.
- The five-year high for Other Gross PP&E Adjustments was -$23.5 million in Q1 2026, with the low at -$65.6 million in Q1 2022.
- Average Other Gross PP&E Adjustments over 5 years is -$47.9 million, with a median of -$50.3 million recorded in 2023.
- Year-over-year, Other Gross PP&E Adjustments plunged 1735.26% in 2022 and surged 42.49% in 2026.
- Tracing CCCC's Other Gross PP&E Adjustments over 5 years: stood at -$60.9 million in 2022, then increased by 4.54% to -$58.1 million in 2023, then rose by 8.02% to -$53.5 million in 2024, then increased by 27.62% to -$38.7 million in 2025, then surged by 39.35% to -$23.5 million in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$23.5 million (Q1 2026), -$38.7 million (Q4 2025), and -$26.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | -23.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.47 Mn |
| Mar 31, 2026 | -23.47 Mn |
| Dec 31, 2025 | -38.70 Mn |
| Dec 31, 2025 | -38.70 Mn |
| Sep 30, 2025 | -26.43 Mn |
| Sep 30, 2025 | -26.43 Mn |
| Jun 30, 2025 | -38.66 Mn |
| Jun 30, 2025 | -38.66 Mn |
| Mar 31, 2025 | -40.81 Mn |
| Mar 31, 2025 | -40.81 Mn |
| Dec 31, 2024 | -53.46 Mn |
| Dec 31, 2024 | -53.46 Mn |
| Sep 30, 2024 | -44.09 Mn |
| Sep 30, 2024 | -44.09 Mn |
| Jun 30, 2024 | -45.70 Mn |
| Jun 30, 2024 | -45.70 Mn |
| Mar 31, 2024 | -47.48 Mn |
| Mar 31, 2024 | -47.48 Mn |
| Dec 31, 2023 | -58.12 Mn |
| Dec 31, 2023 | -58.12 Mn |
| Sep 30, 2023 | -50.33 Mn |
| Sep 30, 2023 | -50.33 Mn |
| Jun 30, 2023 | -51.70 Mn |
| Jun 30, 2023 | -51.70 Mn |
| Mar 31, 2023 | -52.38 Mn |
| Mar 31, 2023 | -52.38 Mn |
| Dec 31, 2022 | -60.89 Mn |
| Dec 31, 2022 | -60.89 Mn |
| Sep 30, 2022 | -56.53 Mn |
| Sep 30, 2022 | -56.53 Mn |
| Jun 30, 2022 | -59.36 Mn |
| Jun 30, 2022 | -59.36 Mn |
| Mar 31, 2022 | -65.63 Mn |
| Mar 31, 2022 | -65.63 Mn |
| Dec 31, 2021 | -25.60 Mn |
| Dec 31, 2021 | -25.60 Mn |
| Sep 30, 2021 | -3.08 Mn |
| Sep 30, 2021 | -3.08 Mn |
| Jun 30, 2021 | -3.70 Mn |
| Jun 30, 2021 | -3.70 Mn |
| Mar 31, 2021 | -3.64 Mn |
| Mar 31, 2021 | -3.64 Mn |
| Dec 31, 2020 | -5.81 Mn |
| Dec 31, 2020 | -5.81 Mn |
| Sep 30, 2020 | -6.31 Mn |
| Sep 30, 2020 | -6.31 Mn |
| Dec 31, 2019 | -6.76 Mn |
| Dec 31, 2019 | -6.76 Mn |